• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Qure.ai Receives FDA Clearance for AI-Powered Lung Nodule Analysis Tool

by Syed Hamza Sohail 08/23/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– Qure.ai, a global innovator in medical imaging AI, has today announced a pivotal 510(k) FDA clearance for its AI-powered chest CT solution – qCT LN Quant.

– The new AI solution is now available to support radiologists and pulmonologists in analyzing lung nodules on non-contrast chest CT scans and tracking volumetric growth as part of progression monitoring.

Qure.ai Enhances Lung Cancer Care with AI-Powered qCT LN Quant

Qure.ai has integrated qCT LN Quant into its AI-powered lung cancer care continuum in the US, providing comprehensive solutions to identify, measure, manage, and monitor lung health. These tools support clinicians in healthcare institutions, driving early detection and improving patient outcomes.

Key components of Qure.ai’s lung health solutions include:

– qXR LN: Facilitates early detection and localization of lung nodules on chest X-rays, extending lung cancer detection capabilities beyond traditional CT-based screening methods.

– qTrack: A multi-modality lung nodule management platform that integrates seamlessly with Electronic Medical Records (EMRs), enabling clinicians to efficiently find, report, collaborate, and prioritize lung cancer patient cases.

qCT LN Quant offers advanced quantitative characterization of solid lung nodules, with features including:

– Measurement Capabilities:

  – Analysis of average, short-axis, long-axis, and effective diameters of lung nodules.

  – Evaluation of morphological data across single or multiple thoracic studies.

  – Estimation of volume doubling time and tracking nodules over multiple time points.

– Advanced Imaging and Decision Support:

  – Generation of detailed 2D and 3D reconstructions.

  – Calculation of Brock malignancy risk scores.

  – Provision of Fleischner Society guidelines-based management suggestions to ensure consistent and reliable clinical decision-making.

– Reimbursement Eligibility:

  – Potential eligibility under two CPT codes, including tissue quantification CPT 0722T for CT and 3D reconstruction code.

Qure.ai’s solutions are widely trusted globally, with real-world AI deployments at over 3,000 sites across more than 90 countries. The company has established partnerships, commercial deployments, and ongoing research studies with prominent institutions, including AstraZeneca, the UK’s National Health Service (NHS) hospitals, and leading teleradiology companies in the UK and US. Headquartered in Mumbai, Qure.ai operates regional offices in New York and London.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, FDA Clearance

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |